Komori
Astellas Pharma (4503) · InitiativeAchieved

Discontinuation of development of ASP8731/ML-0207

First written in FY2023. 1 of 1 entries say "Achieved", first in FY2023. Latest entry: FY2023.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of Sickle Cell Disease Development for ASP8731/ML-0207A theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2023AchievedAnnual report

    「2023年４月　鎌状赤血球症を対象として第Ⅰ相段階にあったBACH1阻害薬ASP8731／ML-0207の開発を中止したことを公表しました。」

    ミトコンドリア領域のBACH1阻害薬ASP8731／ML-0207について、鎌状赤血球症を対象とする第Ⅰ相開発を中止した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.